While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. Here's What You Should Know About Analysts' Price Targets They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other w ...

"Pyxis Oncology's novel ADC approach and impressive pipeline comprised of next-generation therapeutics are aimed to target difficult-to-treat cancers and improve the quality of life of patients," said Mr. Metzger. "I look forward to working with the deeply experienced board and leadership team assembled at Pyxis Oncology to further advance the Company's mission of improving outcomes for patients with cancer." Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. T ...

– IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial – WALTHAM, Mass., June 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the Company's highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refrac ...

WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting comme ...

Michael Metzger Yigal, thank you for your question. You broke up a little bit, but I think I captured it. So as you know, we've had breakthrough therapy designation for KMT2A. For NPM1, we have the opportunity to potentially get breakthrough therapy, probably most importantly, your first indication. and I think the engagement around KMT2A and the molecule and the submission package has been very strong. We have priority review as well. I think for NPM1, we'll look to leverage some of the same access points ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...

Exhibit 99.1 Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 – – BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected in 4Q24 to potentially support sNDA filing in 1H25 – – Company ...

Organ responses in 0.3 mg/kg Q2W 66% had improvement in skin and joint tightening severity 12 Ab535 is a mouse specific anti-CSF-1R antibody | --- | --- | --- | --- | |--------------------------|-----------------------------------|-----------|------------------------------------------------------------------------------------| | N=135 randomized 2:1 | Axatilimab 0.3 mg/kg Q2W (N=90) | | PRIMARY ENDPOINT ∆ FVC | | to axatilimab or placebo | Placebo Q2W (N=45) | Follow-up | SECONDARY ENDPOINTS Disease progres ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Neil Gallagher - President and Head, R&D Keith Goldan - Chief Financial Officer Dr. Peter Ordentlich - Chief Scientific Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Anupam Rama - JPMorgan Phil Nadeau - TD Cowen Brad Canino - Stifel Michael Schmidt - Guggenheim As ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 32-0162505 (State or Other J ...